

## **TauRx welcomes new Chief Medical Officer, Dr Richard Stefanacci**

**Aberdeen, UK and Singapore, October 6, 2022**

TauRx Pharmaceuticals Ltd, a global leader in tau-based research in Alzheimer's, is delighted to name Dr Richard Stefanacci, an established global key opinion leader in Alzheimer's, as Chief Medical Officer (CMO). This comes alongside appointing strategic regulatory advisors in the UK, US and Canada.

Dr Stefanacci is a US-based Internal Medicine physician and fellowship trained Geriatrician who is an active physician caring for people with Alzheimer's daily.

Strengthening the TauRx team as it prepares to move its lead Alzheimer's treatment through regulatory processes, Dr Stefanacci covers three areas under the acronym "GPS":

- **GOVERNMENT:** Having served as a Centers for Medicare and Medicaid (CMS) Health Policy Scholar, Dr Stefanacci has assisted with the roll out of Medicare Part D, the insurance benefit likely to cover an oral Alzheimer's treatment such as the investigative drug being developed by TauRx.
- **POLICY:** In previous roles as CMO for several managed care organisations, he has gained a deep understanding of payer decision making, benefit design, and formulary management.
- **SYSTEMS:** Focusing on improving population health and delivery through his position as a faculty member at Thomas Jefferson University, Jefferson College of Population Health, where he teaches, publishes, and consults with health systems in the US, Europe and Asia.

In addition to Dr Stefanacci and the ongoing work with EVERSANA™ advisory teams, TauRx has enlisted regulatory legal counsel at King & Spalding, and UK-based advisors, Niche Science & Technology, to support regulatory submissions. These appointments will supplement the TauRx team to prepare for a successful commercial launch to treat Alzheimer's disease with the aim to transform the lives of millions globally.

Dr Stefanacci will continue serving as the Chief Medical Officer for EVERSANA, a role that he has held for over 11 years. EVERSANA is a leading independent provider of global services to the life sciences industry.

**ENDS**

### **ABOUT TAURx PHARMACEUTICALS LTD**

The TauRx group of companies was established in 2002 in Singapore, continuing a partnership with the University of Aberdeen, with primary research facilities and operation based in Aberdeen, UK. The company has dedicated the past two decades to developing treatments and diagnostics for Alzheimer's and other neurodegenerative diseases due to protein aggregation pathology.

Alzheimer's dementia is a leading cause of death throughout the world and one of the most important public health issues to be addressed globally. TauRx will contribute to addressing this unmet need with data from LUCIDITY and pursuit of Medicines and Healthcare products Regulatory



Agency (MHRA) approval through the Innovative Licensing and Access Pathway (ILAP), having been granted an Innovation Passport, the first stage of the process, in May this year.

TauRx plans to submit HMTM for regulatory approval in the US and Canada in 2023, with other territories to follow, in line with its overall plans to commercialise HMTM and pursue clinical trials in other related neurodegenerative diseases.

For more information: [www.taurx.com](http://www.taurx.com)

**Media Contacts**

**Leona Minellas, Communication Director**

Aspect: The Strategic Communication Experts

[Leona.minellas@aspectreputation.com](mailto:Leona.minellas@aspectreputation.com)

+44 (0) 7311 823947



<https://news.cision.com/taurx>